Back to Ophthalmology



Neovascular Age-Related Macular Degeneration Market Research

What is Neovascular Age-Related Macular Degeneration (nAMD)?

Neovascular age-related macular degeneration (nAMD, exudative, wet AMD) is a prevalent, progressive retinal degenerative macular disease that is characterized by neovascularization of the choroid, mainly affecting the elderly population, causing gradual vision impairment. Current therapeutic advancements slow the progression of the disease but do not cure or reverse its course. Newer therapies, including gene therapies, offer potential new targets for treatment.

Spherix Global Insights – Ophthalmology – Neovascular Age-Related Macular Degeneration (nAMD)

Spherix’s Ophthalmology team covers the Neovascular Age-Related Macular Degeneration (nAMD) market in our RealTime Dynamix, Launch Dynamix, Patient Chart Dynamix, and Special Topix services. Spherix’s has the following studies publishing this year covering Neovascular Age-Related Macular Degeneration (nAMD):

  • RealTime Dynamix™: Neovascular Age-Related Macular Degeneration (US)
  • Launch Dynamix™: Vabysmo (Roche/Genentech) in Age-Related Macular Degeneration (US)
  • Launch Dynamix™: Byooviz (Samsung Bioepis and Biogen) Ranibizumab Biosimilar (US)
  • Launch Dynamix™: Cimerli (Coherus BioSciences) Ranibizumab Biosimilar (US)
  • Launch Dynamix™: Eylea HD in Neovascular Age-Related Macular Degeneration (US)
  • Patient Chart Dynamix™: Treatment Switching in Neovascular Age-Related Macular Degeneration (US)
  • Patient Chart Dynamix™: New Starts in Neovascular Age-Related Macular Degeneration (US)
  • Special Topix™: Ophthalmology Biosimilars Today and Tomorrow (US)

*Pending approvals and launch

Spherix’s Launch Dynamix™ service consists of two parts: monthly KPI tracking and quarterly deep dives. Monthly KPIs provide benchmarking of newly launched products for the first eighteen months of commercial availability, and quarterly deep dive reports includes promotional activity, barriers to uptake, and patient types gravitating to the launch brand.

Spherix’s RealTime Dynamix™ service includes US quarterly deep dive reports and a Canadian semiannual report. Core content is supplemented with new variables each wave to provide both tracking of KPIs and an infusion of fresh market-driven insights.

Spherix’s Patient Chart Dynamix™ service includes patient-level data detailing clinical and non-clinical patient demographics, along with rationale for treatment choices. It reveals real patient management patterns through rigorous analysis of large-scale patient chart audits.

Spherix’s Special Topix™ service is an independent service that includes access to a report or series of reports based on current events or topics of interest in specialty markets covered by Spherix.

Follow Spherix Ophthalmology on Social Media

Follow us for ophthalmology industry news, insights & analysis:


For Guests & Current Clients

For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here:


Blaine Cloud
Franchise Leader, Ophthalmology
Email: [email protected]


Get more information on Neovascular Age-Related Macular Degeneration Coverage